Copyright
©The Author(s) 2020.
World J Clin Oncol. May 24, 2020; 11(5): 275-282
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.275
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.275
Trade name | API | Yr | Sponsor | Excipients1 | Form | Storage condition |
Skyrizi | Risankizumab-rzaa | 2019 | Abbvie | Disodium succinate hexahydrate, polysorbate 20, sorbitol, and succinic acid | Liquid | 2-8 °C, avoid light/shake/freeze |
Evenity | Romosozumab-aqqg | 2019 | Amgen | Acetate, calcium, polysorbate 20, and sucrose | Liquid | 2-8 °C, avoid light/shake/freeze |
Cablivi | Caplacizumab-yhdp | 2019 | Ablynx/Ablynx | Citrate dihydrate, polysorbate-80, sucrose, and trisodium citrate dihydrate | Lyophilized Powder | 2-8 °C, avoid light /freeze |
Trogarzo | Ibalizumab-uiyk | 2018 | TaiMed Biologics/ Theratechnologies | L-histidine, polysorbate 80, sodium chloride, sucrose | Liquid | 2-8 °C, avoid light/shake/freeze |
Ilumya | Tildrakizumab | 2018 | Sun pharma | L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose | Liquid | 2-8 °C, avoid light/shake/freeze |
Crysvita | Burosumab-twza | 2018 | Ultragenyx pharmaceutical/kyowa hakko kirin | L-histidine, L-methionine, polysorbate 80, D-sorbitol | Liquid | 2-8 °C, avoid light/shake/freeze |
Aimovig | Erenumab-aooe | 2018 | AmgenNovartis | Acetate, polysorbate 80, sucrose | Liquid | 2-8 °C, avoid light/shake/freeze |
Poteligeo | Mogamulizumab-kpkc | 2018 | Kyowa hakko kirin | Citric acid monohydrate, glycine, polysorbate 80 | Liquid | 2-8 °C, avoid light/shake/freeze |
Takhzyro | Lanadelumab | 2018 | Dyax/ Shire | Citric acid monohydrate, L-histidine, sodium chloride, sodium phosphate dibasic dihydrate | Liquid | 2-8 °C, avoid light/shake/freeze |
Lumoxiti | Moxetumomab pasudotox-tdfk | 2018 | AstraZeneca | Glycine, polysorbate 80, sodium phosphate monobasic monohydrate, sucrose | Lyophilized Powder | 2-8 °C, avoid light/shake/freeze |
Ajovy | Fremanezumab-vfrm | 2018 | Teva | Disodium ethylenediaminetetraacetic acid dihydrate (EDTA), L-histidine, L-histidine hydrochloride monohydrate, polysorbate-80, sucrose | Liquid | 2-8 °C, avoid light/shake/freeze |
Emgality | Galcanezumab-gnlm | 2018 | Eli Lilly | L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sodium chloride | Liquid | 2-8 °C, avoid light/shake/freeze |
Libtayo | Cemiplimab-rwlc | 2018 | Regeneron/Sanofi | L-histidine, L-histidine monohydrochloride monohydrate, sucrose, L-proline, polysorbate 80 | Liquid | 2-8 °C, avoid light/shake/freeze |
Buffer system | Controlled pH range (25 °C) | Acid | Base | Example product |
Phosphate | 5.8-7.8 | Monosodium phosphate | Disodium phosphate | Tysabri® |
Acetate | 3.8-5.8 | Acetic acid | Sodium acetate | Amgevita® |
Citrate | 3.0-7.4 | Citric acid | Sodium citrate | Humira® |
Succinate | 3.3-6.6 | Succinic acid | Sodium succinate | Kadcyla® |
Tris | 7-9 | Tris-HCl | Tris | Besponsa® |
- Citation: Zhang Y, Williams III RO, Tucker HO. Formulation strategies in immunotherapeutic pharmaceutical products. World J Clin Oncol 2020; 11(5): 275-282
- URL: https://www.wjgnet.com/2218-4333/full/v11/i5/275.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i5.275